Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Zinc Supplementation With Targeted Immunotherapy for Advanced Hepatocellular Carcinoma
NCT07793695Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of zinc in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of USTC. Started Sep 2026; status: recruiting.
02
Drugs
zinc
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07793695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793695.